Medical/Pharmaceuticals

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its interim results for the six-months endedJune 30, 2023, and provided updates on multiple milestones achieved since the beginning of 2023. Dr. Jay Mei, Antengene's F...

2023-08-25 19:37 2101

Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth

SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 interim results. In the first half of 2023, Henlius reported a boost in operating profits ofRMB240.0 million and revenues of RMB2.5005 billion, up by 93.9% YoY, driven by growth in core oncology products. HANQUYOU (trast...

2023-08-25 19:26 5202

Tigermed Reports 2023 Interim Results

HANGZHOU, China, Aug. 25, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...

2023-08-25 18:39 3257

Zhiyi Biotech Announced First Subject Dosed in the U.S. Phase 1 clinical Trial of SK10, in Development for Treatment of Chemotherapy-induced Diarrhea

GUANGZHOU, China, Aug. 25, 2023 /PRNewswire/ -- On August 23rd 2023, Zhiyi Biotech announced that the first three subjects have been dosed in the U.S. Phase 1 clinical trial of SK10, an innovative heat-killed Bacteroides fragilis product developed by Zhiyi Biotech for Chemotherapy-induced Diarrhe...

2023-08-25 18:19 1314

GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics

YONGIN, South Korea, Aug. 25, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a MOU at its headquarters in Yongin,South Korea with Eubiologics for a co-production of Euvichol, an oral cholera vaccine. Under the MOU, bo...

2023-08-25 15:14 1430

AsiaMedic Sets New Standard in Healthcare with Installation of First SIGNA™ Hero 3.0T MRI Scanner in Asia-Pacific

SINGAPORE, Aug. 25, 2023 /PRNewswire/ -- AsiaMedic , a leading health screening and diagnostic imaging specialist, has taken a groundbreaking leap in healthcare innovation with the installation of the first-ever SIGNA™ Hero 3.0T magnetic resonance imaging (MRI) sca...

2023-08-25 14:12 2077

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced

HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximatelyRMB3,783.8 million, up 22.3% on a yearly basis. Gross profit was approximatelyRMB3,201.6 million, up ...

2023-08-25 10:06 4035

Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy

SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Ph...

2023-08-25 08:15 1955

Antheia Achieves Major Commercial Milestone

Company's first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMs and APIs MENLO PARK, Calif., Aug. 25, 2023 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the...

2023-08-25 08:01 1746

Laekna, Inc. (2105.HK) Announces Interim Results 2023

* For the Phase II pivotal trial of Afuresertib (LAE002) + Paclitaxel for platinum-resistant recurrent ovarian cancer (PROFECTOR-II), the patients were fully enrolled and the topline data is expected in the late fourth quarter of 2023 * For the Phase Ib/III trial of Afuresertib + Fulvestrant ...

2023-08-25 08:00 3250

YS Biopharma Announces Purchase of Shares by Company Officers

GAITHERSBURG, Md., Aug. 25, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-08-25 04:15 2082

Ping An Health announces 2023 interim results

Managed care business delivers robust performance  Market leadership in corporate health management drives loss narrowing by 47.2% HONG KONG and SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or "Ping An Health", Stock Code: 1833.H...

2023-08-24 20:58 8437

Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that the New Drug Application (NDA) for its...

2023-08-24 20:00 1350

Vittra APS Unique composite by FGM is appointed as a solution to a clinical problem by the renowned agency Dental Advisor

JOINVILLE, Brazil, Aug. 24, 2023 /PRNewswire/ -- The Vittra APS Unique composite, by FGM Dental Group, was recognized for its chameleon effect in the publication Clinical Problem Solvers of the renowned American agency Dental Advisor - a global reference in the field of dentistry. In the publicat...

2023-08-24 18:00 1501

111, Inc. Announces Second Quarter 2023 Unaudited Financial Results

SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the second quar...

2023-08-24 14:00 2969

MRI Software's first 'Voice of the Strata Manager' report reveals unseen pressures of high-demand real estate industry job

Despite dealing with difficult behaviour from owners and 50+ hour work weeks, strata managers are optimistic about the future of their jobs and industry SYDNEY, Aug. 24, 2023 /PRNewswire/ -- A new national 'Voice of the Strata Manager' report reveals an alarming number of Australian strata manage...

2023-08-24 13:02 2282

PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor

TOKYO, Aug. 23, 2023 /PRNewswire/ -- PeptiGrowth Inc (PeptiGrowth), a Japanese biotechnology company focusing on the development of synthetic peptide based growth factors and Orizuru Therapeutics, Inc(OZTx), a Japanese biopharmaceutical company focusing on the research and development of iPSC-de...

2023-08-24 09:51 1344

Everest Medicines Announces Interim Results for First Half of 2023

SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, ...

2023-08-24 08:15 3544

Samsung Biologics appoints new leadership to oversee quality and regulatory affairs

- Distinguished industry leaders with extensive track records in quality assurance and regulatory affairs join Samsung Biologics to support the company's quality-driven business operation. INCHEON, South Korea, Aug. 23, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract d...

2023-08-24 07:59 1420

Salvia BioElectronics: First-Ever Patient Treated with Breakthrough Neuromodulation Solution for Severe Migraine and Cluster Headache in Australia

NAMBOUR, Australia, Aug. 24, 2023 /PRNewswire/ -- In a remarkable medical milestone, an Australian patient at Nambour Selangor Private Hospital became the first-ever patient to receive Salvia BioElectronics' paper-thin neuromodulation solution for severe migraine and cluster headache. This groun...

2023-08-24 05:45 1483
1 ... 83848586878889 ... 578